Delivery Order SPE2DB20D9329-SPE2DB25FZK13

Award Date 5/5/25
Potential Completion Date 5/27/25
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,424.46 contract is for the delivery of Xolair 300 mg/2 ml autoinjector units, with a period of performance through January 9, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,273.38 contract is for the delivery of Xolair 300 mg/2 ml autoinjector medication to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,712.23 contract is for the delivery of Xolair 300 mg/2 ml autoinjectors to support the medical supply needs of military healthcare facilities. The contract has an ultimate completion date of March 17, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group holds a $499,999,999...
This is a $7,704.99 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Xolair 150 mg/ml autoinjectors and has a performance period through May 27, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $11,985.60 contract is for the supply of Xolair 300 mg/2 ml auto-injectors to support the medical needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $34,244.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of Xolair 300 mg/2 ml auto-injector products to support the medical needs of military healthcare facilities. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA, which allows the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of Xolair 300 mg/2 ml autoinjectors, valued at $1,712.23, with a period of performance through May 2, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery...
This is a $25,683.45 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of 4,568,169,700 units of Xolair 300 mg/2 ml autoinjectors with a completion date of May 21, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,273.38 contract is for the delivery of Xolair 300 mg/2 ml autoinjector 2 ml injections. The contract has an ultimate completion date of January 23, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive...
This is a firm fixed-price delivery order contract awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,273.38 contract was awarded by the Defense Logistics Agency (DLA) on July 24, 2024, with a completion date of August 14, 2024. The contract is for the delivery of Xolair 300 mg/2 ml autoinjector to support the recurring medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group...
  • SPE2DB20D9329
    Indefinite Delivery Contract
  • SPE2DB20D9329-SPE2DB25FZK13
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Xolair 300 mg/2 ml autoinjector, with a ceiling value of $10,273.38 and a period of performance through May 27, 2025.

DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories.

Generated 8/4/25, 9:48 AM